The HER2-specific tyrosine kinase inhibitor zongertinib was well tolerated and demonstrated promising efficacy in patients with HER2 mutation-positive non-small cell lung cancer, meeting the primary endpoint of the Beamion LUNG-1 Phase Ib Cohort 1 study, according to research presented today at the International Association for the Study of Lung Cancer 2024 World Conference on Lung Cancer.
Older Men Increasingly Overtreated for Prostate Cancer, Study Suggests
Overtreatment of older prostate cancer patients with a limited life expectancy has increased over the past two decades among men receiving care in the Veterans
November 12, 2024